Ibrutinib and rituximab trigger 95 percent response rate among CLL patients
Nearly all of the high-risk chronic lymphocytic leukemia patients in a
phase II clinical trial responded to treatment with the targeted therapy
ibrutinib and the antibody rituximab, researchers reported today, at
the 55th Annual Meeting of the American Society of Hematology.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Hematology | Leukemia | Rituxan